News

Regeneron's baloncibart cuts heart-rate surge and symptoms in POTS in Phase 2 PINNACLE trial

What's the deal? Regeneron has reported results from the Phase 2 PINNACLE trial of baloncibart, a first-in-class antibody being developed for postural orthostatic tachycardia syndrome (POTS), a condition in which standing up triggers an abnormal surge in heart rate, dizziness and fatigue. A single subcutaneous dose of baloncibart reduced the exaggerated heart-rate response to standing and improved orthostatic symptoms for up to four weeks, with biomarker changes suggesting the drug expands blood volume. The data were presented on 12 November 2026 at the American Autonomic Society's annual meeting.

Why it matters: POTS has no FDA-approved therapies, and current care is limited to symptom management. Baloncibart works by blocking NPR1, a receptor involved in regulating blood volume; the hypothesis is that freeing this pathway increases circulating volume, which dampens the heart's over-reaction to standing. In the trial, 150 mg (n=27) and 450 mg (n=28) doses were compared with placebo (n=27): the drug improved orthostatic symptoms (12.9-point improvement vs baseline on a symptom scale, nominal p=0.0096) and physical functioning (13.8-point improvement, nominal p=0.0073). It was generally well tolerated with mild side effects, and Regeneron plans a potentially pivotal Phase 3 trial in the first half of 2027.

Read more: Regeneron, 12 November 2026

More top stories